Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This price reduction will make broad molecular diagnostics accessible to more patients with cancer.
Robert Jan Lamers, Managing Director of Hartwig Medical Foundation:
“Every patient with cancer deserves access to the best possible diagnostics and treatment. By lowering the price, molecular diagnostics become available to more patients, supporting clinicians in selecting the bestt treatment options for their patients.”
The price reduction has been made possible by the implementation of the Illumina NovaSeq X-Plus sequencing platform, on which WGS has been validated for diagnostic use. Hartwig will also continue to contribute to the costs to further promote the use of WGS for patients.
OncoAct WGS can be used as reimbursed diagnostics for cancer of unknown primary (CUP/PTO), non-small cell lung cancer (NSCLC), and for determining responsiveness to NTRK-inhibitors, regardless of tumor type, subject to agreement with health insurers.
For AYA patients (Adolescents and Young Adults), OncoAct WGS remains free of charge for hospitals as part of the KWF-funded GENAYA-project. More information is available at GENAYA.nl.
Do you have any questions? Please consult with us.
You read an article in the category Whole genome sequencing. You may also be interested in Hartwig Medical Foundation, Lab process, Molecular diagnostics, OncoAct All newsAlso read
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
GENAYA Extended: More Care and Research
The GENAYA project has been extended by two years. This gives researchers more time to collect genetic tumor data from …
Measuring the effects of radiotherapy on cancer may open up avenues for treatment
Radiotherapy works by damaging the DNA of cancer cells. It’s an effective strategy overall, but many cancers have subsets of …
It is important to unravel the DNA in rare types of cancer; 21% of patients with cancer have a rare form.